Keros Therapeutics, Inc. (NASDAQ: KROS) is a Healthcare company (Biotechnology) with a market capitalization of $222M. The Maz Rating grades it against the other companies in its sector.
Keros Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $11.31, Keros Therapeutics, Inc. trades at 5.4x sales and 0.8x book value, with an EV/EBITDA of 0.4. Over the last twelve months it generated about $41M of revenue and a net loss of $56M. It runs a gross margin of 98.0%, an operating margin of -179.7% and a net margin of -151.4%. It shows return on equity of -21.8%, return on invested capital of -24.6% and a free cash flow yield of -21.7%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 18.14. Over the past 52 weeks the share price ranged from $8.98 to $22.55, with a beta of 1.02.
Keros Therapeutics, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 10 Buy and 7 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.